UNDERVALUED News & Analysis

We believe the proposed merger is value neutral but shares cheap.

These stocks are still cheap despite impressive earnings. 

Fair value uneffected by suspended early-stage clinical trials.

A near monopoly in Australia pushes this company into global markets but progress has been slow.

This undervalued share provides the opportunity for investors that look beyond the markets short-sighted view. 

These companies could offer good value and, as of the latest data and have the stamp of approval from Morningstar Gold Medalist equity funds.

Solid global sales and margin expansion are highlights from latest quarter.

We believe the company is in a transition year and results will improve.

A potential opportunity for income investors who are interested in high levels of current income.

These high-quality companies are our top picks for investors wanting to boost their domestic exposure.